Submit Your Directory FREE WEBSITE SUBMISSION. BEST WEBSITE PROMOTION.

The BRAF (V600E) mutation analysis is predictive for anti-EGFR therapies (i.e., cetuximab and panitumumab). BRAF mutations account for approximately 12-15% of colorectal cancer patients. Keywords : PI3K, EML4-ALK, BRAF, KRAS, EGFR, Pulmotype, KRAS Mutation, BRAF Mutation .

The phosphoinositide 3-kinase (PI3K)/AKT1 pathway is acknowledged as a key component of cell survival. Activated by receptors or the small GTPase Ras, the various PI3K isoforms phosphorylate inositol lipids to form second messenger phosphoinositides. PI3K family members have long been accepted as oncogenes.